| 000 | 01892 a2200553 4500 | ||
|---|---|---|---|
| 005 | 20250517184312.0 | ||
| 264 | 0 | _c20190308 | |
| 008 | 201903s 0 0 eng d | ||
| 022 | _a1476-5365 | ||
| 024 | 7 |
_a10.1038/bmt.2017.211 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aWais, V | |
| 245 | 0 | 0 |
_aReduced-toxicity conditioning for allogeneic hematopoietic cell transplantation in elderly or comorbid patients with AML using fludarabine, BCNU and melphalan: disease stage at transplant determines outcome. _h[electronic resource] |
| 260 |
_bBone marrow transplantation _c01 2018 |
||
| 300 |
_a94-96 p. _bdigital |
||
| 500 | _aPublication Type: Letter; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xpharmacology |
| 650 | 0 | 4 |
_aCarmustine _xpharmacology |
| 650 | 0 | 4 | _aComorbidity |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHematopoietic Stem Cell Transplantation _xmethods |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Myeloid, Acute _xdrug therapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aMelphalan _xpharmacology |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 |
_aTransplantation Conditioning _xmethods |
| 650 | 0 | 4 |
_aTransplantation, Homologous _xmethods |
| 650 | 0 | 4 |
_aVidarabine _xanalogs & derivatives |
| 700 | 1 | _aKündgen, L | |
| 700 | 1 | _aBohl, S R | |
| 700 | 1 | _avon Harsdorf, S | |
| 700 | 1 | _aSchlenk, R F | |
| 700 | 1 | _aDöhner, K | |
| 700 | 1 | _aTeleanu, V | |
| 700 | 1 | _aBullinger, L | |
| 700 | 1 | _aNguyen, T M | |
| 700 | 1 | _aDrognitz, K | |
| 700 | 1 | _aMoulin, J-C | |
| 700 | 1 | _aBinnenhei, M | |
| 700 | 1 | _aBentz, M | |
| 700 | 1 | _aDöhner, H | |
| 700 | 1 | _aBunjes, D | |
| 700 | 1 | _aKuchenbauer, F | |
| 700 | 1 | _aRinghoffer, M | |
| 773 | 0 |
_tBone marrow transplantation _gvol. 53 _gno. 1 _gp. 94-96 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1038/bmt.2017.211 _zAvailable from publisher's website |
| 999 |
_c27781696 _d27781696 |
||